;Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.
We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements contained in this press release.
Use of non-GAAP Financial InformationA reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release. CONTACT:
Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific CorporationBOSTON SCIENTIFIC CORPORATIONCONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS
(Unaudited)Three Months EndedYear EndedDecember 31,December 31,in millions, except per share data
8,188Cost of products sold
1,3421,3695,2075,612Operating expenses:Selling, general and administrative expenses
6836492,5802,635Research and development expenses
3741185191Loss on program termination16Amortization expense
132129513511Goodwill impairment charge1,817Intangible asset impairment charges26512Purchased research and development421C
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Related medicine technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System2
. Boston Scientific Responds to DOJ Civil Lawsuit3
. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.4
. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent5
. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent6
. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan7
. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results8
. Boston Scientific to Acquire Atritech9
. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease10
. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article11
. Boston Scientific Completes Acquisition of Sadra Medical